A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma

Trial Profile

A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs BMS 986183 (Primary) ; Nivolumab
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 26 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 15 May 2017 Planned End Date changed from 22 Sep 2020 to 22 Oct 2020.
    • 15 May 2017 Planned primary completion date changed from 30 Dec 2019 to 21 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top